Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

BACKGROUND: Neoadjuvant chemotherapy (NACT) for early breast cancer can make breast-conserving surgery more feasible and might be more likely to eradicate micrometastatic disease than might the same chemotherapy given after surgery. We investigated the long-term benefits and risks of NACT and the in...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757427/
https://www.ncbi.nlm.nih.gov/pubmed/29242041
http://dx.doi.org/10.1016/S1470-2045(17)30777-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757427/
https://www.ncbi.nlm.nih.gov/pubmed/29242041
http://dx.doi.org/10.1016/S1470-2045(17)30777-5

Ejemplares similares